Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis

Inflammation Research

Volumn 63, Issue 4, 2014, Pages 309-315

  Pereira, Michelly Cristiny ^a   Cardoso, Pablo Ramon Gualberto ^a   Da Rocha, Laurindo Ferreira ^a,b   Rêgo, Moacyr Jesus Barreto Melo ^a   Gonçalves, Sayonara Maria Calado ^a   Santos, Flaviana Alves ^a   Galdino Pitta, Marina Rocha ^a   Dantas, Andréa Tavares ^a,b   Duarte, Ângela Luzia Branco Pinto ^b   Pitta, Maira Galdino Da Rocha ^a  

^a Laboratório de Imunomodulação e Novas Abordagens Terapêuticas Núcleo de Pesquisa Em Inovação Terapêutica Suely Galdino   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Cytokines; Disease activity; Rheumatoid arthritis; Statins

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 6; IONOMYCIN; PHORBOL 13 ACETATE 12 MYRISTATE; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE ACTIVITY SCORE FOR 28 JOINTS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ANALYSIS; REMISSION; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 84896546662     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-013-0702-4     Document Type: Article

References (39)

1. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(Suppl 3):S265-72.
2. Marques Neto JF, Gonçalves ET, Barros EFO, Cunha MFL, Radominski S, Oliveira SM, et al. Estudo multicêntrico da prevalência da artrite reumatóide do adulto em amostras da população brasileira. Rev Bras Reumatol. 1993; 33(5):169-73.
3. Liao KP, Solomon DH. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). 2013;52(1):45-52.
4. Yildiz M. Arterial distensibility in chronic inflammatory rheumatic disorders. Open Cardiovasc Med J. 2010;4:83-8.
5. Colin EM, Asmawidjaja PS, van Hamburg JP, Mus AM, van Driel M, Hazes JM, et al. 1,25-Dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum. 2010;62(1):132-42.
6. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol. 1999;162(3):1246-51. (Pubitemid 29306992)
7. Brennan FM, Mcinnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Investig. 2008;118(11):3537-45.
8. Lubberts E. Th17 cytokines and arthritis. Semin Immunopathol. 2010;32(1):43-53.
9. Kanda H, Yokota K, Kohno C, Sawada T, Sato K, Yamaguchi M, et al. Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod Rheumatol. 2007;17(5):364-8. (Pubitemid 47593482)
10. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004;363(9426):2015-21. (Pubitemid 38781100)
11. Shirinsky IV, Zheltova OI, Solovyova NY, Kozlov VA, Shirinsky VS. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand J Rheumatol. 2009;38(1):23-7.
12. Blaschke S, Viereck V, Schwarz G, Klinger HM, Guerluek S, Müller GA. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand J Rheumatol. 2009;38(4):235-9.
13. Mccarey DW, Sattar N, Mcinnes IB. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? Arthritis Res Ther. 2005;7(2):55-61. (Pubitemid 40439439)
14. Lazzerini PE, Lorenzini S, Selvi E, Capecchi PL, Chindamo D, Bisogno S, et al. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol. 2007;25(5):696-700. (Pubitemid 350284842)
15. Yokota K, Miyazaki T, Hirano M, Akiyama Y, Mimura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol. 2006;33(3):463-71. (Pubitemid 43334566)
16. De Vera MA, Choi H, Abrahamowicz M, Kopec J, Lacaille D. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2012;64(6):809-16.
17. Sheng X, Murphy MJ, Macdonald TM, Wei L. Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. J Rheumatol. 2012;39(1):32-40.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24. (Pubitemid 18091653)
19. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8.
20. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796-806.
21. Ferraz MB, Oliveira LM, Araujo PM, Atra E, Tugwell P. Crosscultural reliability of the physical ability dimension of the health assessment questionnaire. J Rheumatol. 1990;17(6):813-7. (Pubitemid 20213508)
22. Sokka T, Häkkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis. 2004;63(5):494-7. (Pubitemid 38530191)
23. Tran CN, Lundy SK, Fox DA. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology. 2005;12(3):183-9. (Pubitemid 41375641)
24. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51(Suppl 5):v3-11.
25. Komatsu N, Takayanagi H. Autoimmune arthritis: the interface between the immune system and joints. Adv Immunol. 2012;115:45-71.
26. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11(1):88-95. (Pubitemid 26026748)
27. García-Bermúdez M, López-Mejías R, González-Juanatey C, Corrales A, Robledo G, Castañeda S, Miranda-Filloy JA, et al. Analysis of the interferon gamma (rs2430561, +874T/A) functional gene variant in relation to the presence of cardiovascular events in rheumatoid arthritis. PLoS One. 2012;7(10):e47166.
28. Cañete JD, Martínez SE, Farrés J, Sanmartí R, Blay M, Gómez A, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis. 2000;59(4):263-8. (Pubitemid 30305567)
29. Firestein GS. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol. 2005;11(3 Suppl):S39-44. (Pubitemid 40863818)
30. da Rocha LF Jr, Duarte ÂL, Dantas AT, Mariz HA, Pitta Ida R, Galdino SL, et al. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. J Rheumatol. 2012;39(7):1320-5.
31. Tang TT, Song Y, Ding YJ, Liao YH, Yu X, Du R, et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res. 2011;52(5):1023-32.
32. Kumar P, Kennedy G, Khan F, Pullar T, Belch JJ. Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study. Scott Med J. 2012;57(2):80-3.
33. Tristano AG, Fuller K. Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int Immunopharmacol. 2006;6(12):1833-46. (Pubitemid 44574489)
34. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol. 1997;17(8):1521-6. (Pubitemid 27387772)
35. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol. 2001;21:1327-32. (Pubitemid 34219840)
36. Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol. 2004;173:7641-6. (Pubitemid 39628206)
37. Khattri S, Zandman-Goddard G. Statins and autoimmunity. Immunol Res. 2013;56(2-3):348-57.
38. Roman-Blas JA, Jimenez SA. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthr Cartil. 2006;14(9):839-48. (Pubitemid 44138675)
39. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49(10):497-505.